2006-2007 Grant Cycle : Research Grants Awarded
Basic, Clinical and Translation
Human and Mouse Linked Evaluation of Tumors (HAMLET)
Matthew Ellis, MB, PhD, FRCP
Washington University in St. Louis
Tumor Cell Biology VI
$300,000
Project Connect: Enhancing Connections During Breast Cancer
Annette Stanton, PhD
The Regents of the University of California, Los Angeles
Psychosocial and Complementary Treatment Approache
$227,367
Cohesion-dependent Mechanisms of Cancer Progression and Aneuploidy
Robert V. Skibbens, Ph.D
Lehigh University
Tumor Cell Biology V
$257,172
Cancer Stem Cells and Breast Cancer Recurrence
Lewis Chodosh, M.D., Ph.D.
The Trustees of the University of Pennsylvania
Tumor Cell Biology II
$300,000
Early detection of chemotherapy associated cardiotoxicity in women with breast cancer
William Hundley, MD
Wake Forest University Health Sciences
Detection/Diagnosis/Prognosis
$299,222
Antibody-NKG2D Ligand Fusion Protein for Breast Cancer Therapy
Seung-Uon Shin, Ph.D.
University of Miami School of Medicine
Detection/Diagnosis/Prognosis
$300,000
A novel DNA/peptide based library for breast cancer therapy
Ben Park, M.D., Ph.D.
Johns Hopkins University
Tumor Cell Biology III
$300,000
An Integrated Approach to Biomarker Validation in Patients with HER-2 Positive Metastatic Breast Cancer Treated with Rapamycin and Trastuzumab
Maysa Abu-Khalaf, MD
Yale University
Tumor Cell Biology IV
$300,000
N'N'Diarylurea Inhibitors of Translation Initiation for Treatment of Breast Cancer
Huseyin Aktas, D.V.M., Ph.D.
Harvard Medical School
Treatment
$300,000
A Functional Genomic Approach to Develop More Rational Taxane Combination Therapies for Metastatic Breast Cancer
David Azorsa, Ph.D.
The Translational Genomics Research Institute
Treatment
$299,999
Molecular Imaging of Breast Cancer with breast PET/CT
Ramsey Badawi, Ph.D.
The Regents of the University of California (University of California Davis)
Detection/Diagnosis/Prognosis
$299,954
Breast Cancer Brachytherapy Using Nanoparticle-Carried Therapeutic Radionuclides
Ande Bao, PhD
Univ of Texas Health Science Center at San Antonio
Treatment
$282,377
p16 Mediated supression of hTERT in Breast Cancer
Alexey Bazarov, Ph.D.
The Regents of the University of California, San Francisco
Detection/Diagnosis/Prognosis
$297,032
A novel interaction of Focal Adhesion Kinase and p53 in breast cancer cells
Vita Golubovskaya, Ph.D.
University of Florida
Tumor Cell Biology I
$300,000
Characterisation of the mammary epithelial cell hierarchy and implications for breast cancer
Jane Visvader, Ph.D.
The Walter & Eliza Hall Institute of Medical Research
Tumor Cell Biology I
$300,000
Regulatory T Cells and Breast Cancer Risk
Kirsten Moysich, Ph.D.
Roswell Park Cancer Institute Alliance Foundation
Risk, Prevention and Epidemiology
$300,000
The role of apoptosis gene variants in familial breast cancer
Nicola Camp, Ph.D.
University of Utah
Risk, Prevention and Epidemiology
$300,000
Novel Regulators of EGFR Signaling in Breast Cancer
Karl Chai, Ph.D.
University of Central Florida
Tumor Cell Biology I
$300,000
Telomere dysfunction-induced senescence as a barrier for the development of breast carcinomas
Sandy Chang, MD, PhD
University of Texas M.D. Anderson Cancer Center
Tumor Cell Biology V
$300,000
Cell cycle-dependent regulation of human BRCA2 gene expression by SLUG and PRDX5C
Gautam Chaudhuri, Ph.D.
Meharry Medical College
Tumor Cell Biology I
$300,000
Genome-wide mapping of MicroRNA binding sites in breast cancer cells and associated fibroblasts
Izhak Haviv, Ph.D
The University of Melbourne
Tumor Cell Biology VI
$300,000
A New Mechanism of Breast Cancer Progression
Henry Heng, Ph.D.
Wayne State University
Detection/Diagnosis/Prognosis
$300,000
Combined effects of a sulfoxide-containing anticancer prodrug and Herceptin against breast cancer
Kun-Ming Chen, Ph.D.
Penn State College of Medicine
Treatment
$294,951
Inhibitors of eIF4E/eIF4G Interaction as Potential Anti-Breast Cancer Drugs
Michael Chorev, Ph.D.
Harvard Medical School
Treatment
$300,000
Role of Cyr61(CCN1) in Breast Cancer Tumor Progression
Lidija Covic, Ph.D.
New England Medical Center Hospitals, Inc.
Tumor Cell Biology VI
$300,000
A Personalized Approach for the Treatment of Metastatic Breast Cancer
Paul Hergenrother, Ph.D.
The Board of Trustees of the University of Illinois at Urbana-Champaign
Treatment
$300,000
Immunotherapeutic Synergy Between Chemotherapy and A Breast Cancer Vaccine
Leisha Emens, M.D., Ph.D.
Johns Hopkins University
Tumor Cell Biology IV
$300,000
The Role of Therapy-Induced Autophagy and Apoptosis in Metastatic Breast Cancer Response
Joan Bull, M.D.
The University of Texas Health Science Center at Houston
Detection/Diagnosis/Prognosis
$300,000
Collagen receptors as novel targets to lower the breast cancer risk associated with high mammographic density
Wolfgang Vogel, PhD
University of Toronto
Tumor Cell Biology I
$300,000
Novel Natural Products for Breast Cancer Prevention and Treatment
Hui (Hannah) Wang, MD, PhD
The University of Alabama at Birmingham
Treatment
$300,000
Combining vaccines and adoptive T cell transfer for breast cancer immunotherapy
Philip Darcy, PhD, BSc
Peter MacCallum Cancer Centre
Tumor Cell Biology III
$272,478
A role for Pnck as a sensitizer to breast cancer therapeutics.
Tushar Deb, Ph.D.
Georgetown University
Tumor Cell Biology VI
$296,348
Clinical Assessment of Cytochrome P450 (CYP)3A4 Induction by Tamoxifen: Potential Impact of Hormonal and Genetic Factors
Pankaj Desai, Ph.D.
University of Cincinnati
Treatment
$297,968
Identifying the immunologic signature of early stage breast cancer using the neu-transgenic mouse to model the immunogenicity of human breast cancer
Mary Disis, M.D.
University of Washington
Detection/Diagnosis/Prognosis
$300,000
Expression of estrogen receptor in breast cancer stem cells
Gabriela Dontu, M.D., Ph.D.
The Regents of the University of Michigan
Detection/Diagnosis/Prognosis
$300,000
Reducing the Anti-apoptosis BRUCE Protein level Activates p53 Apoptosis Pathway and Sensitizes Breast Cancer Cells to Chemotherapy-induced Apoptosis
Chunying Du, Ph.D.
Stowers Institute for Medical Research
Tumor Cell Biology III
$300,000
Breast Sound Speed: A Potential Predictor of Breast Cancer Risk
Neb Duric, Ph.D.
Barbara Ann Karmanos Cancer Institute
Risk and Prevention, Epidemiology
$299,941
Circadian Control of Breast Cancer Development
Carla Finkielstein, Ph.D.
Virginia Polytechnic Institute and State University
Tumor Cell Biology I
$300,000
The Role of Six1, and its target TGF beta R-I, in mediating breast cancer metastasis
Heide Ford, B.S., M.S., Ph.D.
Regents of the University of Colorado, University of Colorado at Denver and Health Sciences Center (UCDHSC) - Fitzsimons Campus
Tumor Cell Biology II
$300,000
Targeting the Hedgehog Pathway in the Treatment of Breast Cancer
Andra Frost, M.D.
The University of Alabama at Birmingham
Treatment
$300,000
Refined Prediction of Hormone Response
Suzanne A. W. Fuqua, Ph.D
Baylor College of Medicine
Detection/Diagnosis/Prognosis
$299,998
Cyclin D1 as a marker of DCIS recurrence
Doris Germain, PhD
Mount Sinai School of Medicine
Tumor Cell Biology V
$299,877
Defining the role of EpCAM in breast cancer invasion
William Gillanders, M.D.
Washington University in St. Louis
Tumor Cell Biology V
$300,000
Detection of Early Stages of Breast Cancer Metastasis
Dave Hoon, PhD
John Wayne Cancer Institute
Detection/Diagnosis/Prognosis
$300,000
Behavior Activation for Depressed Cancer Patients: Randomized Trial
Derek Hopko, B.A., M.A., Ph.D.
The University of Tennessee
Treatment
$296,267
A Longitudinal Study of Alterations in Cognitive Function and Brain Metabolites among Women Receiving Chemotherapy for Primary Breast Cancer.
Sadhna Kohli, Ph.D
University of Rochester
Psychosocial and Complementary Treatment Approache
$300,000
Signaling by ErbB/HER Family Receptors in Breast Cancer Cell Membranes
John Koland, Ph.D.
The University of Iowa
Tumor Cell Biology II
$300,000
Human papilloma viruses and human breast cancer
James Lawson, MD
The University of New South Wales (UNSW)
Risk, Prevention and Epidemiology
$300,000
Focus on Apical Polarity to Develop Breast Cancer Prevention Strategies
Sophie Lelièvre, D.V.M., Ph.D.
Purdue University
Risk and Prevention, Epidemiology
$300,000
Accurate Breast Cancer Prognosis
Jian Li, Ph.D.
University of Florida
Detection/Diagnosis/Prognosis
$216,763
Breast cancer: Molecular pathophysiology of paclitaxel-induced pain
Wolfgang Liedtke, MD, PhD
Duke University Medical Center
Treatment
$300,000
Predicting Response to First-line Trastuzumab: eTag Analysis of Primary Breast Tumor Predictive Factors, and Metastatic Serum Biomarker Analysis
Allan Lipton, M.D.
The Pennsylvania State University College of Medicine
Detection/Diagnosis/Prognosis
$296,521
Role of erbB3 in erbB2/neu-mediated Breast Cancer Development
Bolin Liu, M.D.
Regents of the University of Colorado, University of Colorado at Denver and Health Sciences Center (UCDHSC) - Fitzsimons Campus
Tumor Cell Biology V
$300,000
The Role of Deleted in Breast Cancer 1 (DBC1) in SirT1 Regulation and Tumorigenesis
zhenkun lou, Ph.D.
Mayo Clinic Rochester
Tumor Cell Biology I
$295,509
To Test a Culturally Sensitive Intervention among Chinese Breast Cancer Survivors Using Expressive Writing
Qian Lu, Ph.D., M.D.
The Regents of the University of California, Los Angeles
Psychosocial and Complementary Treatment Approache
$300,000
Boosting Immunity to Metastatic Breast Cancer Using Targeted T Cells: A Phase II Clinical Trial
Lawrence Lum, M.D.
Wayne State University
Treatment
$300,000
Multi-parameter molecular imaging of tumor susceptibility and early evaluation of therapeutic response
Umar Mahmood, M.D., Ph.D.
Massachusetts General Hospital (The General Hospital Corp.)
Detection/Diagnosis/Prognosis
$300,000
Potential values of CAPC in early detection, treatment, and prevention of breast cancer invasion
Yan-gao Man, M.D., Ph.D.
American Registry of Pathology, Inc.
Detection/Diagnosis/Prognosis
$300,000
Disintegrins as a Therapeutic and Imaging Agent for Metastatic Breast Cancer
Francis Markland, Ph.D.
USC/University of Southern California
Detection/Diagnosis/Prognosis
$300,000
Glyolysis, IRS-2 and Metastatic Breast Cancer
arthur mercurio, Ph.D.
University of Massachusetts Medical School
Tumor Cell Biology II
$300,000
Cell Cycle Inhibition Therapy:Stathmin As A Potential Therapeutic Target For Breast Cancer
Sucharita Mistry, Ph.D
Mount Sinai School of Medicine
Tumor Cell Biology IV
$300,000
Thiamine starvation with thiaminase I for breast cancer therapy
Jeffrey Moscow, M.D., Dartmouth Medical School, 1982
University of Kentucky Research Foundation
Tumor Cell Biology III
$300,000
Low-toxicity Retinoids to Prevent the Recurrence of ER- Breast Cancer
Donald Muccio, Ph.D.
The University of Alabama at Birmingham
Risk, Prevention and Epidemiology
$300,000
Multivalent VRP-Based Immunotherapy for Breast Cancer
Edward Nelson, M.D.
The Regents of the University of California (Irvine)
Tumor Cell Biology III
$299,958
A Novel Strategy to Find New Genetic Risk Factors for Breast Cancer
Stanley Nelson, M.D.
The Regents of the University of California, Los Angeles
Detection/Diagnosis/Prognosis
$289,216
Adverse neurological consequences of breast cancer treatments: Causes and prevention
Mark Noble, Ph.D.
University of Rochester
Psychosocial and Complementary Treatment Approache
$299,940
PTEN in the Breast Tumor Microenvironment
Michael Ostrowski, PhD
The Ohio State University Research Foundation
Tumor Cell Biology II
$300,000
Targeting Langerhans cells for therapeutic vaccination in breast cancer
Anna Palucka, M.D., Ph.D.
Baylor Research Institute
Treatment
$299,643
Anti-HER2/neu IgE for the Therapy of Breast Cancer
Manuel Penichet, M.D., Ph.D.
The Regents of the University of California, Los Angeles
Treatment
$299,988
Regulating of MMP Secretion During the Invasion of Breast Cancer Cells
Rytis Prekeris, Ph.D.
Regents of the University of Colorado, University of Colorado at Denver and Health Sciences Center (UCDHSC) - Fitzsimons Campus
Tumor Cell Biology II
$299,993
Epidermal growth factor receptor (EGFR)-related protein (ERRP), a novel pan-erbB inhibitor, is a potential targeted therapy for breast cancer.
Arun Rishi, Ph.D.
Wayne State University
Tumor Cell Biology V
$299,961
Molecular Therapeutics of Breast-Associated Cancer Lymphedema
Stanley Rockson, M.D.
Stanford University
Treatment
$300,000
A Phase I Trial of Continuous Low-Irradiance Photodynamic Therapy for Post-Mastectomy Chest Wall Recurrences of Breast Cancer
Gary Rogers, MD
New England Medical Center Hospitals, Inc.
Treatment
$264,233
Epigenetic Silencing of BRCA-1 and Protective Effects of Dietary Components
Donato Romagnolo, Ph.D.
Arizona Board of Regents, University of Arizona
Tumor Cell Biology VI
$300,000
Elucidating the contribution of bone to breast cancer metastasis using an engineered bone scaffold
Michael Rosenblatt, M.D.
TUFTS UNIVERSITY
Tumor Cell Biology II
$300,000
Identification of breast cancer intravasation genes
Thomas Rosol, D.V.M., Ph.D
The Ohio State University Research Foundation
Tumor Cell Biology VI
$300,000
Gene Profiling and in vivo Imaging in Characterizing the Metastatic Phenotype Regulated by the Type I IGF Receptor in Breast Cancer
Deepali Sachdev, Ph.D.
University of Minnesota - Twin Cities
Tumor Cell Biology IV
$300,000
A Phase-II Pre-Clinical Study of Paclitaxel-Monoclonal Antibody Conjugates for Targeted Chemotherapy of Breast Cancer
Ahmad Safavy, PhD
The University of Alabama at Birmingham
Treatment
$300,000
Role of Aryl Hydrocarbon Receptor and Cross Talk with Estrogen Receptor in Response of Breast Cancer Cells to the Novel Antitumor Agent Aminoflavone
Edward Sausville, M.D.
University of Maryland, Baltimore
Treatment
$300,000
Vascular-targeted photodynamic therapy (VTP), imaging (VTI) and on-line prognosis of ductal carcinoma in situ (DCIS) using novel BCLs and BCL-RGDs.
Avigdor Scherz, Ph.D.
Weizmann Institute of Science
Detection/Diagnosis/Prognosis
$300,000
Targeting AlphaVBeta3 Integrin and Src to Alleviate Breast Cancer Progression Stimulated by TGF-beta
William Schiemann, Ph.D.
Regents of the University of Colorado, University of Colorado at Denver and Health Sciences Center (UCDHSC) - Fitzsimons Campus
Tumor Cell Biology II
$300,000
The Role of Beta1 and Beta4 Integrins in Endocrine and Anti-HER Therapy Resistance in Breast Cancer
Rachel Schiff, Ph. D.
Baylor College of Medicine
Tumor Cell Biology III
$299,926
Diagnostic and Therapeutic Strategies Targeting the c-Myc Oncoprotein
Rosalie Sears, Ph.D.
Oregon Health & Science University
Tumor Cell Biology I
$299,983
Development of Small Molecule Activator of Death Receptor for Breast Cancer Therapy
Sharmila Shankar, Ph.D.
The University of Texas Health Center at Tyler
Tumor Cell Biology III
$300,000
The MCM2-7 complex and breast cancer
Naoko Shima, Ph.D.
University of Minnesota - Twin Cities
Tumor Cell Biology V
$300,000
Aged Stroma in Breast Tumorigenesis: Development of an In Vivo Model
Sheila Stewart, Ph.D.
Washington University in St. Louis
Tumor Cell Biology II
$300,000
Design, Synthesis and Evaluation of XIAP inhibitors as a Novel Therapy for the Treatment of Human Breast Cancer
Haiying Sun, Ph.D.
The Regents of the University of Michigan
Treatment
$300,000
Evaluation of immune response to HERV antigens as vaccines for breast cancer
Feng Wang-Johanning, M.D. and Ph.D.
University of Texas M.D. Anderson Cancer Center
Treatment
$299,290
Tumor-Targeted rVSV-F Vectors for Treatment of Metastatic Breast Cancer
Savio Woo, Ph.D.
Mount Sinai School of Medicine
Treatment
$300,000
Regulation of SRC-3/AIB1 Function by Akt/PKB Kinase Signaling Pathway and the Potential Role in Endocrine Therapy Resistance
Ray-Chang Wu, Ph.D.
Baylor College of Medicine
Tumor Cell Biology I
$300,000
BRCA1 Regulates AKT1 Activity in Breast Cancer
Qin Yang, Ph.D., M.D.
Washington University in St. Louis
Tumor Cell Biology V
$300,000
Activating innate immunity to fight breast cancer
Jinghua Yang, Ph.D.
Boston VA Research Institute, Inc.
Risk, Prevention and Epidemiology
$298,932
Mechanisms Of IRF-1 Induced Apoptosis In Breast Cancer
John Yim, MD
University of Pittsburgh
Tumor Cell Biology III
$300,000
Discovery of novel ligands for breast cancer-related microRNA precursors
Yohei Yokobayashi, Ph.D.
The Regents of the University of California (University of California Davis)
Tumor Cell Biology V
$300,000
Serum Epigenetic Markers and the Early Detection of Breast Cancer
Anne Zeleniuch-Jacquotte, M.D.
New York University School of Medicine
Detection/Diagnosis/Prognosis
$186,724
Breast tumor exosomal Jak3BP inhibits myeloid cell differentiation
huang-ge zhang, PhD
The University of Alabama at Birmingham
Tumor Cell Biology III
$300,000
Molecular Biomarkers to Predict Local Recurrence of Breast Cancer
Yun-Ling Zheng, Ph.D.
Georgetown University
Risk, Prevention and Epidemiology
$300,000
* Pending executed agreement
